METHYLSULFONYL SUBSTITUTED MURRAYANINE-CHALCONE COMPOUND AS ANTI-BREAST CANCER AGENTS: SCREENING AGAINST MCF-7 CELL LINE

  • Debarshi Kar Mahapatra Department of Pharmaceutical Chemistry, Dadasaheb Balpande College of Pharmacy, Nagpur 440037, Maharashtra, India
  • Ruchi S Shivhare Department of Pharmaceutical Chemistry, Kamla Nehru College of Pharmacy, Nagpur 441108, Maharashtra, India

Abstract

Introduction: In the normal course, the activity of murrayanine is very minimal and the most attractive way to improve the anti-proliferative activity involves semi-synthesis. Previously, hybrids of murrayanine (tert-butyl containing, thiazole-linked, uracil-fused) have been screened by our research group which showed promising enhancement (several-folds) in the activity. Objective: In the present research, (E)-1-(1-methoxy-9H-carbazol-3-yl)-3-(4-(methylsulfonyl)phenyl)prop-2-en-1-one was screened against breast cancer cell line MCF-7 employing the SRB assay and studied to establish its IC50 value in comparison with the standard drug. The synergistic anti-cancer activity of the combination of carbazole scaffold (eminent anti-neoplatic effect), murrayanine moiety (fair anti-proliferative agent), chalcone scaffold (prominent anti-cancer activity), and methylsulfonyl component in the para position of the ring-B (high anti-tumor potential) was explored considerably. Results: The anti-breast cancer potential of the substituted murrayanine-chalcone was found to be quite incredible as indicated by the IC50 value of 37.16 μM in comparison with the positive control capecitabine (IC50 value of 6.49 μM). Conclusion: The methylsulfonyl group substituted murrayanine-chalcone scaffold produced noteworthy anti-proliferative activity against breast cancer cell line MCF-7. The present interesting study will inspire the researchers and will positively provide directions towards the future rational development of potential low-molecular-weight ligands with profound anti-cancer activity.

Author Biographies

Debarshi Kar Mahapatra, Department of Pharmaceutical Chemistry, Dadasaheb Balpande College of Pharmacy, Nagpur 440037, Maharashtra, India

Assistant Professor,

Department of Pharmaceutical Chemistry,

Dadasaheb Balpande College of Pharmacy,

Nagpur 440037, Maharashtra, India

Ruchi S Shivhare, Department of Pharmaceutical Chemistry, Kamla Nehru College of Pharmacy, Nagpur 441108, Maharashtra, India

Assistant Professor,

Department of Pharmaceutical Chemistry,

Kamla Nehru College of Pharmacy,

Nagpur 441108, Maharashtra, India

References

Mahapatra DK, Bharti SK. Drug Design. New Delhi: Tara Publications Private Limited, 2016.

Vardanyan R, Hruby V. Synthesis of essential drugs. 1st Ed. Amsterdam: Elsevier Science; 2006.

Shivhare RS, Mahapatra DK, Nair RR, Deshmukh SN. Schiff’s base derivatives of murrayanine demonstrated enhanced anti-oxidant activity than its parent moiety. (2016) Indian J Pharm Edu Res 50(4): 9-15.

Mahapatra DK, Das D, Shivhare RS, Borkar SS. Murrayanine-hydantoin and -thiohydantoin analogs as promising anti-convulsant agents: Synthesis, Characterization and Molecular Docking Studies. MOJ Bioorg Org Chem 2018;2(2):47-51.

Mahapatra DK, Dadure KM, Shivhare RS. MCF-7 cell line screening of some uracil containing murrayanine based (thio)-semicarbazide hybrids. Innovat Int J Med Pharm Sci 2018; 3(5): 14-16.

Mahapatra DK, Das D, Shivhare RS. Substituted thiazole linked murrayanine-Schiff’s base derivatives as potential anti-breast cancer candidates: Future EGFR Kinase inhibitors. Int J Pharm Sci Drug Res 2017; 9(3): 139-144.

Mahapatra DK, Shivhare RS, Kumar P. Tert-butyl Group bearing Murrayanine-chalcone Produced Noteworthy Anti-proliferative Activity against Breast Cancer Cell Line. J Adv Res BioChem Pharmacol 2018;1(3&4):4-6.

Mahapatra DK, Asati V, Bharti SK. Chalcones and their role in management of diabetes mellitus: Structural and pharmacological perspectives. Eur J Med Chem 2015;92:839-865.

Mahapatra DK, Bharti SK. Therapeutic Potential of chalcones as cardiovascular agents. Life Sci 2016;148:154-172.

Mahapatra DK, Bharti SK, Asati V. Chalcone Derivatives: Anti-inflammatory Potential and Molecular Targets Perspectives. Curr Top Med Chem 2017;17(28):3146-69.

Mahapatra DK, Bharti SK, Asati V. Anti-cancer Chalcones: Structural and molecular targets perspectives. Eur J Med Chem 2015; 98: 69-114.

Mahapatra DK, Bharti SK, Asati V. Chalcone scaffolds as anti-infective agents: Structural and molecular target perspectives. Eur J Med Chem 2015;101:496-524.

Gibson NW, Erickson LC, Kohn KW. DNA damage and differential cytotoxicity produced in human cells by 2-chloroethyl (methylsulfonyl) methanesulfonate (NSC 338947), a new DNA-chloroethylating agent. Cancer Res 1985;45(4):1674-9.

Brent TP, Lestrud SO, Smith DG, Remack JS. Formation of DNA interstrand cross-links by the novel chloroethylating agent 2-chloroethyl (methylsulfonyl) methanesulfonate: suppression by O6-alkylguanine-DNA alkyltransferase purified from human leukemic lymphoblasts. Cancer Res 1987;47(13):3384-7.

Gibson NW, Hartley JA, Strong JM, Kohn KW. 2-Chloroethyl (methylsulfonyl) methanesulfonate (NSC-338947), a more selective DNA alkylating agent than the chloroethylnitrosoureas. Cancer Res 1986;46(2):553-7.

Finch RA, Shyam K, Penketh PG, Sartorelli AC. 1, 2-Bis (methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino) carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res 2001;61(7):3033-8.

Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S, Demby VE. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl) oxy] phenyl}-6-[5-({[2-(methylsulfonyl) ethyl] amino} methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Disposit 2009;37(2):439-42.

Ismail B, Ghezali L, Gueye R, Limami Y, Pouget C, Leger DY, Martin F, Beneytout JL, Duroux JL, Diab-Assaf M, Fagnere C. Novel methylsulfonyl chalcones as potential antiproliferative drugs for human prostate cancer: Involvement of the intrinsic pathway of apoptosis. Int J Oncol 2013;43(4):1160-8.

Hardy JR, Harvey VJ, Paxton JW, Evans P, Smith S, Grove W, Grillo-Lopez AJ, Baguley BC. Phase I Trial of the Amsacrine Analogue 9-({2-Methoxy-4-[(methylsulfonyl) amino]-phenyl}] amino)-N, 5-dimethyl-4-acridinecarboxamide (CI-921). Cancer Res 1988;48(22):6593-6.

Mahapatra DK, Shivhare RS. Anti-microbial Perspective of a Chalcone, (E)-1-(1-methoxy-9H-carbazol-3-yl)-3-(4-(methylsulfonyl)phenyl)prop-2-en-1-one: Fabrication of a Hybrid by Unification of a Natural Product with a Synthetic Component. Int J Agr Life Sci 2018;4(2):236-240.

Padole CD, Amdare MD, Jogdand KR, Kathane LL, Kuhite NG, Mahapatra DK. Discovery of 4-methyl-2-oxo-2H-chromen-7-yl-2-benzamidoacetate as Anti-proliferative Agent. Int J Ayur Pharm Chem 2018; 8(1): 62-68.

Published
2019-02-15
How to Cite
Kar Mahapatra, D., & Shivhare, R. S. (2019). METHYLSULFONYL SUBSTITUTED MURRAYANINE-CHALCONE COMPOUND AS ANTI-BREAST CANCER AGENTS: SCREENING AGAINST MCF-7 CELL LINE. Mintage Journal of Pharmaceutical and Medical Sciences (ISSN: 2320-3315), 1-3. Retrieved from http://mjpms.in/index.php/mjpms/article/view/423